{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:17:44Z","timestamp":1767892664405,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40263-019-00670-y","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T17:10:17Z","timestamp":1569949817000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain\u2013Barr\u00e9 Syndrome and Narcolepsy"],"prefix":"10.1007","volume":"34","author":[{"given":"Julia","family":"Stowe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"670_CR1","unstructured":"World Health Organization. The power of vaccines: still not fully utilized. 2019. https:\/\/www.who.int\/publications\/10-year-review\/vaccines\/en\/. Accessed 27 Sep 2019."},{"issue":"6","key":"670_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/adc.87.6.493","volume":"87","author":"N Andrews","year":"2002","unstructured":"Andrews N, Miller E, Taylor B, Lingam R, Simmons A, Stowe J, et al. Recall bias, MMR, and autism. Arch Dis Child. 2002;87(6):493\u20134.","journal-title":"Arch Dis Child"},{"key":"670_CR3","doi-asserted-by":"crossref","unstructured":"Miller E, Stowe J. Vaccine safety surveillance. In: Talbot J, Aronson JK (eds) Stephens\u2019 detection and evaluation of adverse drug reactions.\u00a06th ed. Wiley-Blackwell. 2012.","DOI":"10.1002\/9780470975053.ch13"},{"issue":"5","key":"670_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1586\/14760584.5.5.641","volume":"5","author":"A Hviid","year":"2006","unstructured":"Hviid A. Postlicensure epidemiology of childhood vaccination: the Danish experience. Expert Rev Vaccines. 2006;5(5):641\u20139.","journal-title":"Expert Rev Vaccines."},{"issue":"15\u201316","key":"670_CR5","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.vaccine.2004.01.017","volume":"22","author":"CP Farrington","year":"2004","unstructured":"Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine. 2004;22(15\u201316):2064\u201370.","journal-title":"Vaccine."},{"key":"670_CR6","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/S0264-410X(01)00280-8","volume":"20","author":"N.J. Andrews","year":"2001","unstructured":"Andrews N. Statistical assessment of the association between vaccination and rare adverse events post-licensure. Vaccine. 2001;20 Suppl 1:S49\u201353; (discussion S45\u20138).","journal-title":"Vaccine"},{"issue":"9169","key":"670_CR7","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/S0140-6736(99)01239-8","volume":"353","author":"B Taylor","year":"1999","unstructured":"Taylor B, Miller E, Farrington C, Petropoulos M-C, Favot-Mayaud I, Li J, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet. 1999;353(9169):2026\u20139.","journal-title":"Lancet."},{"issue":"45","key":"670_CR8","doi-asserted-by":"publisher","first-page":"7878","DOI":"10.1016\/j.vaccine.2011.08.069","volume":"29","author":"N Andrews","year":"2011","unstructured":"Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain-Barre syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series. Vaccine. 2011;29(45):7878\u201382.","journal-title":"Vaccine."},{"issue":"3","key":"670_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/adc.84.3.227","volume":"84","author":"E Miller","year":"2001","unstructured":"Miller E, Waight P, Farrington CP, Andrews N, Stowe J, Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child. 2001;84(3):227\u20139.","journal-title":"Arch Dis Child."},{"issue":"32","key":"670_CR10","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1016\/j.vaccine.2016.04.050","volume":"34","author":"J Stowe","year":"2016","unstructured":"Stowe J, Andrews N, Ladhani S, Miller E. The risk of intussusception following monovalent rotavirus vaccination in England: a self-controlled case-series evaluation. Vaccine. 2016;34(32):3684\u20139.","journal-title":"Vaccine."},{"issue":"4","key":"670_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/00006454-200104000-00008","volume":"20","author":"P Kramarz","year":"2001","unstructured":"Kramarz P, France EK, Destefano F, Black SB, Shinefield H, Ward JI, et al. Population-based study of rotavirus vaccination and intussusception. Pediatr Infect Dis J. 2001;20(4):410\u20136.","journal-title":"Pediatr Infect Dis J."},{"issue":"10","key":"670_CR12","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/cid\/cit520","volume":"57","author":"JB Carlin","year":"2013","unstructured":"Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R, et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia\u2019s National Immunization Program. Clin Infect Dis. 2013;57(10):1427\u201334.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"670_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1365-2125.2003.01790.x","volume":"55","author":"C Black","year":"2003","unstructured":"Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol. 2003;55(1):107\u201311.","journal-title":"Br J Clin Pharmacol."},{"key":"670_CR14","doi-asserted-by":"publisher","first-page":"f794","DOI":"10.1136\/bmj.f794","volume":"346","author":"E Miller","year":"2013","unstructured":"Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine: retrospective analysis. BMJ. 2013;346:f794.","journal-title":"BMJ."},{"issue":"5","key":"670_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.5665\/sleep.5752","volume":"39","author":"J Stowe","year":"2016","unstructured":"Stowe J, Andrews N, Kosky C, Dennis G, Eriksson S, Hall A, et al. Risk of narcolepsy after AS03 adjuvanted pandemic A\/H1N1 2009 influenza vaccine in adults: a case-coverage study in England. Sleep. 2016;39(5):1051\u20137.","journal-title":"Sleep."},{"issue":"4","key":"670_CR16","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ije\/22.4.742","volume":"22","author":"CP Farrington","year":"1993","unstructured":"Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22(4):742\u20136.","journal-title":"Int J Epidemiol."},{"key":"670_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.smrv.2017.06.006","volume":"38","author":"TO Sarkanen","year":"2018","unstructured":"Sarkanen TO, Alakuijala APE, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep Med Rev. 2018;38:177\u201386.","journal-title":"Sleep Med Rev."},{"key":"670_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2807\/1560-7917.ES2013.18.38.20587","volume":"18","author":"G Amirthalingam","year":"2013","unstructured":"Amirthalingam G, Gupta S, Campbell H. Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review. Euro Surveill. 2013;18:38.","journal-title":"Euro Surveill."},{"issue":"25\u201326","key":"670_CR19","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1016\/S0264-410X(03)00302-5","volume":"21","author":"JP Baker","year":"2003","unstructured":"Baker JP. The pertussis vaccine controversy in Great Britain, 1974-1986. Vaccine. 2003;21(25\u201326):4003\u201310.","journal-title":"Vaccine."},{"issue":"8851","key":"670_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/0140-6736(93)91069-X","volume":"341","author":"E Miller","year":"1993","unstructured":"Miller E, Goldacre M, Pugh S, Colville A, Farrington P, Flower A, et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet. 1993;341(8851):979\u201382.","journal-title":"Lancet."},{"issue":"6","key":"670_CR21","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/aje\/kwk045","volume":"165","author":"E Miller","year":"2007","unstructured":"Miller E, Andrews N, Stowe J, Grant A, Waight P, Taylor B. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. Am J Epidemiol. 2007;165(6):704\u20139.","journal-title":"Am J Epidemiol."},{"issue":"Suppl. 2","key":"670_CR22","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/sj.mp.4001163","volume":"7","author":"B Taylor","year":"2002","unstructured":"Taylor B, Lingam R, Simmons A, Stowe J, Miller E, Andrews N. Autism and MMR vaccination in North London; no causal relationship. Mol Psychiatry. 2002;7(Suppl. 2):S7\u20138.","journal-title":"Mol Psychiatry."},{"issue":"3","key":"670_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/adc.2003.048165","volume":"90","author":"E Miller","year":"2005","unstructured":"Miller E, Andrews N, Grant A, Stowe J, Taylor B. No evidence of an association between MMR vaccine and gait disturbance. Arch Dis Child. 2005;90(3):292\u20136.","journal-title":"Arch Dis Child."},{"issue":"3","key":"670_CR24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1542\/peds.2003-1177-L","volume":"114","author":"N Andrews","year":"2004","unstructured":"Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. Thiomerosal exposure in infants and developmental disorders: a retrospective cohort study in the United Kingdom does not support a causal association. Pediatrics. 2004;114(3):584\u201391.","journal-title":"Pediatrics."},{"issue":"12","key":"670_CR25","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.vaccine.2018.02.036","volume":"36","author":"J Mouchet","year":"2018","unstructured":"Mouchet J, Salvo F, Raschi E, Poluzzi E, Antonazzo IC, De Ponti F, et al. Hepatitis B vaccination and the putative risk of central demyelinating diseases: a systematic review and meta-analysis. Vaccine. 2018;36(12):1548\u201355.","journal-title":"Vaccine."},{"issue":"5","key":"670_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1212\/01.WNL.0000138433.61870.82","volume":"63","author":"MA Hernan","year":"2004","unstructured":"Hernan MA, Jick SS, Olek MJ, Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2004;63(5):838\u201342.","journal-title":"Neurology."},{"key":"670_CR27","unstructured":"WHO and UNICEF. Estimates of national immunization coverage. France. https:\/\/www.who.int\/immunization\/monitoring_surveillance\/data\/fra.pdf. Accessed 30 Sept 2019."},{"key":"670_CR28","unstructured":"European Centre for Disease Prevention and Control. Measles vaccination coverage (second dose, 2014\u20132016). 2017. https:\/\/ecdc.europa.eu\/en\/publications-data\/vaccination-coverage-second-dose-measles-containing-vaccine-eueea-2017. Accessed 30 Sept 2019."},{"key":"670_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ebiom.2016.08.042","volume":"12","author":"HJ Larson","year":"2016","unstructured":"Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, et al. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine. 2016;12:295\u2013301.","journal-title":"EBioMedicine."},{"issue":"8","key":"670_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ebiom.2015.06.018","volume":"2","author":"P Verger","year":"2015","unstructured":"Verger P, Fressard L, Collange F, Gautier A, Jestin C, Launay O, et al. Vaccine hesitancy among general practitioners and its determinants during controversies: a national cross-sectional survey in France. EBioMedicine. 2015;2(8):891\u20137.","journal-title":"EBioMedicine."},{"issue":"902","key":"670_CR31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/pmj.76.902.774","volume":"76","author":"U Seneviratne","year":"2000","unstructured":"Seneviratne U. Guillain-Barre syndrome. Postgrad Med J. 2000;76(902):774\u201382.","journal-title":"Postgrad Med J."},{"issue":"2","key":"670_CR32","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/oxfordjournals.aje.a112795","volume":"110","author":"LB Schonberger","year":"1979","unstructured":"Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976\u20131977. Am J Epidemiol. 1979;110(2):105\u201323.","journal-title":"Am J Epidemiol."},{"issue":"31","key":"670_CR33","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1016\/j.vaccine.2015.05.013","volume":"33","author":"LH Martin Arias","year":"2015","unstructured":"Martin Arias LH, Sanz R, Sainz M, Treceno C, Carvajal A. Guillain-Barre syndrome and influenza vaccines: a meta-analysis. Vaccine. 2015;33(31):3773\u20138.","journal-title":"Vaccine."},{"issue":"40","key":"670_CR34","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1016\/j.vaccine.2013.06.032","volume":"31","author":"CN Dodd","year":"2013","unstructured":"Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, et al. International collaboration to assess the risk of Guillain Barre syndrome following influenza A (H1N1) 2009 monovalent vaccines. Vaccine. 2013;31(40):4448\u201358.","journal-title":"Vaccine."},{"issue":"9876","key":"670_CR35","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","volume":"381","author":"DA Salmon","year":"2013","unstructured":"Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, et al. Association between Guillain-Barre syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013;381(9876):1461\u20138.","journal-title":"Lancet."},{"issue":"3","key":"670_CR36","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/aje\/kwn310","volume":"169","author":"J Stowe","year":"2009","unstructured":"Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am J Epidemiol. 2009;169(3):382\u20138.","journal-title":"Am J Epidemiol."},{"issue":"13","key":"670_CR37","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","volume":"35","author":"N Andrews","year":"2017","unstructured":"Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barre syndrome after human papilloma virus vaccine: a self-controlled case-series study in England. Vaccine. 2017;35(13):1729\u201332.","journal-title":"Vaccine."},{"issue":"3","key":"670_CR38","doi-asserted-by":"publisher","first-page":"e33723","DOI":"10.1371\/journal.pone.0033723","volume":"7","author":"M Partinen","year":"2012","unstructured":"Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Hublin C, Linna M, Olsen P, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PloS One. 2012;7(3):e33723.","journal-title":"PloS One."},{"issue":"2","key":"670_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/joim.12150","volume":"275","author":"I Persson","year":"2014","unstructured":"Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med. 2014;275(2):172\u201390.","journal-title":"J Intern Med."},{"issue":"3","key":"670_CR40","doi-asserted-by":"publisher","first-page":"e33536","DOI":"10.1371\/journal.pone.0033536","volume":"7","author":"H Nohynek","year":"2012","unstructured":"Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PloS One. 2012;7(3):e33536.","journal-title":"PloS One."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-019-00670-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-019-00670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:11:07Z","timestamp":1744715467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-019-00670-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["670"],"URL":"https:\/\/doi.org\/10.1007\/s40263-019-00670-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"assertion":[{"value":"1 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Public Health England, National Infection Service, Immunisation and Countermeasures Division has provided vaccine manufacturers with post-marketing surveillance reports, which the Marketing Authorisation Holders are required to submit to the UK licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julia Stowe, Nick Andrews and Elizabeth Miller have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}